Buy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performance
TipRanksApr 26 02:10 ET
Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline
Seeking AlphaApr 24 11:59 ET
15 Most Black States in the US
Yahoo FinanceApr 22 09:16 ET
Auvelity's Strong Performance Sustains Buy Rating for Axsome Therapeutics
TipRanksApr 16 02:56 ET
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is On The Mark
When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or "P/S") below 2.9x, Axsome Therapeutics, Inc. (NASDAQ:AXSM) looks to be giving off strong sell signals with its 12.1x P/S ratio.
Simply Wall StApr 15 08:37 ET
Express News | Axsome Therapeutics Inc - New Data for Axs-07 in Migraine Demonstrating Efficacy in Pooled Analysis
Moomoo 24/7Apr 15 07:02 ET
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
PDF Version AXS-05 in Alzheimer's disease agitation data featured in oral plenary sessionNew data for AXS-07 in migraine demonstrating efficacy in pooled analysisPresentations on cognitive and wa
Axsome TherapeuticsApr 15 00:00 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
Moomoo 24/7Apr 10 09:35 ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)
TipRanksApr 10 02:21 ET
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
PDF Version NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of ce
Axsome TherapeuticsApr 10 00:00 ET
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
TipRanksApr 8 22:10 ET
Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 2 09:03 ET
Express News | HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Maintains $190 Price Target
Moomoo 24/7Apr 2 08:53 ET
Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential
TipRanksApr 2 06:26 ET
Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)
Yahoo FinanceApr 2 00:17 ET
Axsome Therapeutics(AXSM.US) Officer Sells US$1.9 Million in Common Stock
$Axsome Therapeutics(AXSM.US)$ Officer Jacobson Mark L. sold 24,662 shares of Common Stock on Apr 1, 2024 at an average price of $77.242 for a total value of $1.9 million.Source: Announcement What is
moomoo NewsApr 1 19:26 ET
Form 144 | Axsome Therapeutics(AXSM.US) Officer Proposes to Sell 1.9 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Axsome Therapeutics(AXSM.US)$ Officer Jacobson Mark L. intends to sell 24,662 shares of its common stock on Apr 1, with a total market value of approximately $1.9 milli
moomoo NewsApr 1 18:18 ET
Express News | Axsome Therapeutics Has Initiated ENGAGE Phase 3 Trial Of Solriamfetol, An Investigational Treatment For Binge Eating Disorder In Adults
Moomoo 24/7Apr 1 07:28 ET
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
PDF Version NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of ce
Axsome TherapeuticsApr 1 00:00 ET
Axsome Therapeutics Is Maintained at Buy by Mizuho
Axsome Therapeutics Is Maintained at Buy by Mizuho
Dow JonesMar 28 10:17 ET
No Data
No Data